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Abstract
The cystic fibrosis CFTR chloride channel is involved in pathogen entry into 
epithelial cells, and provides the glutathione and hypochlorous acid necessary for 
bactericidal and viricidal actions. CFTR mutations block these effects, diminishing 
pathogen defence and allowing pathogen accumulation in the extracellular space, 
where antibody encounter is likely. The pathogen antigens observed in cystic fibrosis 
(including P. Aeruginosa, S.Aureus and S.Maltophilia proteins) are homologous to the 
autoantigens reported in cystic fibrosis and all are homologous to the CFTR protein 
itself. Antibodies to pathogens and autoantigens may also target the CFTR protein, 
acting as antagonists, further compromising its function. The tripartite relationship 
between pathogen antigens, autoantigens and the CFTR protein creates a feed forward 
cycle, diminishing the function of the CFTR protein and increasing the probability of 
pathogen accumulation and further antibody encounters at every turn. Kegg pathway 
analysis of the CFTR/autoantigen interactome indicates that the CFTR protein is also 
involved in pathogen entry pathways, diabetes and pancreatic and gastric acid 
secretion pathways, in pathways related to cardiac myopathy, and in the 
gonadotrophin signalling network, all which are relevant to cystic fibrosis. 
Interruption of this cycle by antigen and antibody adsorption, and possible by 





































































Cystic fibrosis is a devastating condition caused by mutations in the cystic 
fibrosis transmembrane conductance regulator CFTR chloride channel. The disease 
affects many organs resulting in general debilitation but especially targets the 
respiratory system leading to difficulty in breathing . There is no apparent cure or 
preventive strategy. The disease appears to have an immune and autoimmune 
component as antibodies to Saccharomyces cerevisiae and  Stenotrophomonas 
Maltophilia{  and to neutrophil cytoplasmic antigens and bactericidal/permeability-
increasing protein (BPI)  and many other proteins (the adrenoreceptor ADRB2, 
Calgranulin,  heat shock proteins, mucins, myeloperoxidase, rheumatoid factor and 
tumour necrosis factor, inter alia are observed in many patients Bae, Choi, et al. 2010 
5301 /id}. The disease is also influenced by infection. For example Burkholderia 
infection causes severe respiratory infections in cystic fibrosis patients and is often 
associated with this condition  (LiPuma, 1998, LiPuma, 1998, Coutinho, 2007). 
Stenotrophomonas maltophilia infection has also been reported to worsen pulmonary 
symptoms  while infection with  S.Aureus or P.Aeruginosa are known to  decrease the 
lifespan of cystic fibrosis patients . 
Many bacteria and viruses cause problems by molecular mimicry of human proteins. 
When homologous to receptors, they may act as decoys, or when homologous to 
peptide ligands that may act as dummy ligands or decoy substrates. For example the 
measles virus V protein is a decoy substrate for IkappaB kinase (Pfaller & 
Conzelmann, 2008). They may also use the host’s cognate receptors to gain entry, as 
is the case with the AIDS virus and the CCR5 or CXCR4 chemokine receptors . When 
such mimics are antigenic and homologous to host proteins they may cause problems 
related to autoimmunity. Such mimicry is extensive (Elde & Malik, 2009)and has 
been observed between Herpes simplex, a risk factor in Alzheimer’s disease, and 
Alzheimer’s disease susceptibility gene products (Carter, 2010b), or between the 
proteins of the Epstein Barr virus or of gut bacterial flora and multiple sclerosis 
autoantigens (Westall, 2006, Toussirot & Roudier, 2008) .
 As reported below, proteins from pathogens implicated in cystic fibrosis, and many 
others (bacteria, fungi and viruses) are homologous to diverse CFTR mutants. Many 
of these homologous regions are immunogenic, suggesting an important autoimmune 
component to cystic fibrosis that may be amenable to therapy.
Methods 
Mutant CFTR proteins were identified from the Cystic fibrosis mutation database 
http://www.genet.sickkids.on.ca/app
A “polymutant” protein was constructed (Fig 1) that included 19 point mutations, and 
was used for bioinformatics analysis. The sequence of this protein as well as the 
common DeltaF508 deletion mutation was compared with viral, bacterial and fungal 
proteins using the NCBI BLAST server . Heptapeptides centred on the point mutation 
were also screened against viral and bacterial proteomes.  Pathogen antigen and 
autoantigens described in cystic fibrosis were aligned with the delta508 mutant using 
the Uniprot CLUSTAL alignment server http://www.uniprot.org/. Antigenicity was 
predicted using the immune epitope database server 























































































3programmes are calculated on the basis of charge, hydrophobicity and surface 
localisation.  B cell antigenicity was determined using the BepiPred linear epitope 
prediction method {Larsen, Lund, et al. 2006 1725 /  (See Table 1 for the predicted 
antigenicity of individual amino acids) and T cell antigenicity using the Average 
Relative Binding matrix methods that predicts IC50 values for the binding of epitopes 
to major histocompatibility complex (MHC) molecules . The B cell antigenicity of the 
native and mutant proteins can be directly compared, as the algorithm defines 
antigenicity, amino acid by amino acid, along the length of the protein. In contrast, T 
cell epitopes are referenced as 9 amino acid strings, and each mutation generates a 
series of epitopes that are distinct from those in the native protein. There are 
numerous T cell epitopes across multiple HLA-antigens and the native/mutant 
comparisons were restricted to HLA DRB1*0301, one of the most common alleles .
The CFTR interactome was downloaded from the  Protein, Signalling, Transcriptional 
Interactions & Inflammation Networks Gateway (pSTIING) database 
http://pstiing.licr.org/ and pathway analysis performed at KEGG pathways . 
http://www.genome.jp/kegg/tool/color_pathway.html . Host proteins interacting with 
viruses were obtained from the VirusMint database 
http://mint.bio.uniroma2.it/virusmint/ and from the Herpes/host viral interaction 
database (Carter, 2010c) http://www.polygenicpathways.co.uk/herpeshost.html
The BLAST analyses return a large number of hits to multiple proteins from hundreds 
of bacterial, viral and fungal species. The CFTR protein is homologous to several 
proteins from the same species, resulting in a certain number of overall hits per 
species. These were semi-quantitatively analysed using a tag cloud server at 
http://www.tagcloud-generator.com/generator.php#anker which generates tags, sized 
according to the number of hits per species. The tag size was set to a font size of 4 to 
30. Because of the large volume of data generated by the BLAST analyses, the 
original saved BLAST searches and the maps of the KEGG pathway analysis are 
stocked in an online database at http://www.polygenicpathways.co.uk/cysfib.htm
Results
The immunity spectrum of the CFTR mutants.
The localisation of the mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) that were examined is depicted in Fig 1. 
Several of these mutations are in regions of high predicted B-cell antigenicity 
(R171H, G480C, G551D, S895N, K1250A, N1303K) while others are less so (Fig 2).
The CFTR F508 deletion or point mutations can dramatically change the 
antigenicity, not only of the amino acid concerned, but also of the surrounding peptide 
as shown in Fig 2. For example the F508Del mutant markedly increases the predicted 
B-cell antigenicity over a long stretch of amino acids, not only confined to the deleted 
amino acid and also generates two T cell epitopes that have a higher affinity (1.5 - 3-
fold) than those of the native protein (Fig 3). For the 19 other mutants, B cell 
antigenicity can be increased, decreased or little changed by the point mutation (Fig 
2). 
The T cell epitope landscape is dramatically changed by the 19 point 
mutations as shown in Fig 2. All of these sequences are T cell epitopes and will bind 
to MHC molecules, although with different affinities. High concentrations of antigens, 























































































4(see below), might be expected to saturate all MHC binding sites.  57 T cell epitopes 
were generated by the polymutant protein, compared to 50 for the native protein. The 
following epitope changes resulted in large increases in T cell epitope affinity 
( LSHGHKQLM  > LSHDHKQLM (127 fold); ITLSGGQRA  > ITLSGDQRA (63 
fold); CVLSHGHKQ  > CVLSHDHKQ (63 fold); FDDMESIPA  > FDDMESIRA (6 
fold); IAIYLGIGL  > IAIYLCIGL (3.9 fold); DMESIPAVT  > DMESIRAVT (5.2 
fold). Certain epitopes in the native protein are lost due to the mutation (N=27), while 
others are gained (N=34), many of which were of intermediate T cell affinity (Fig 2).
The ten T cell epitopes (mutant Delta F508 protein) with the highest affinity 
are homologous to proteins expressed by a number of bacterial species, including 
S.Aureus.  Other noteworthy species containing CFTR epitope homologues included 
Clostridial species, and Klebsiellae (Table 2, which are known to colonise CF patients 
(see Table 3). This type of epitope mapping may be of use in identifying novel 
pathogen suspects that may pose a problem in cystic fibrosis. For example, proteins 
from B.cereus and Brachyspira species were well represented as CFTR epitope 
matches (See Table 2).
F508del CFTR homology with autoantigens and pathogen proteins
The F508del mutant protein is homologous to ten autoantigens and four 
P.Aeruginosa and S.Maltophilia antigens reported in cystic fibrosis. The autoantigens 
are in turn homologous to proteins from three major pathogens implicated in cystic 
fibrosis (S.Aureus, P.Aeruginosa and S.Maltophilia) (Table 4), suggesting that the 
autoantigens are likely to have been created by antibodies that initially targeted the 
pathogen proteins. The Blast results for this exercise are available at 
http://www.polygenicpathways.co.uk/cftrpathant.htm 
CFTR/pathogen protein homologies
Several viral or bacterial pathogens colonise cystic fibrosis patients to a much 
greater extent than observed with the normal population . Many of these pathogens 
have been reported to worsen symptomatology, for example S.Maltophilia  and even 
to decrease the lifespan of infected patients (S.Aureus or P.Aeruginosa)  . These 
effects are summarised in Table 3. 
The heptapeptides surrounding the 19 point mutations, or the octapeptide surrounding 
the F508del mutation, are all homologous to proteins expressed by S.Aureus, 
P.Aeruginosa or S.Maltophilia, (Table 5 ) as well as to many other strains (not shown: 
see website BLASTs) . 
The delta508 mutant or the entire polymutant is also homologous to proteins 
expressed by multiple viral, bacterial and fungal strains, many of which, in particular 
P.Aeruginosa, S.Aureus and S.Maltophilia, are known to hypercolonise cystic fibrosis 
patients or to be associated with symptom exacerbation (Table 6). This survey also 
identified many other pathogens expressing proteins with CFTR homology, which 
might perhaps be considered as potential antibiotic targets. These included B.Cereus, 























































































5The CFTR protein, mutated or not, contains a large number of T cell epitopes (82,376: 
vs. various MHC alleles) of which 1303 were of high affinity (< 100nM). The 
pathogen protein homology with the 10 highest affinity epitopes is shown in Table 7. 
Numerous pathogen species are represented, with  P.Aeruginosa. S.Aureus and 
S.Maltophilia figuring highly as pathogens expressing proteins with homology to 
theses CFTR epitopes.
P.Aeruginosa and S.Aureus vatches in the mutant CFTR protein
Vatches (Viral mATCHES are short contiguous amino acid stretches covering the 
entire human proteome that are identical in human, and viral proteins and also in the 
proteins of other pathogens ( see http://www.polygenicpathways.co.uk/blasts.htm
. They are a probable legacy of our evolutionary decent from microorganisms, and of 
pathogen mimicry of human proteins: Despite chromosomal shuffling over millions of 
years, the current human DNA  can still encode for quite large peptide stretches that 
are identical to those expressed by pathogen proteins (Carter, 2010d, Carter, 2010a, 
Carter, 2010b). The S.Aureus and P.Aeruginosa vatches within the CFTR polymutant 
are shown in Fig 4. The CFTR polymutant displays extensive homology with proteins 
expressed by these two pathogens. The homologous regions are often within highly 
immunogenic regions of the CFTR and pathogen proteins, and also cover the CFTR 
point mutations.
Homology with the native CFTR protein
As the mutations in cystic fibrosis are point mutations, the native protein too is 
evidently homologous to these same pathogen proteins. However, the pathogen 
riddance pathways are intact in these cases, and the immune system is not 
compromised by CFTR mutations. There is no reason to suppose that high levels of 
pathogen proteins could be attained, or that the host could not appropriately deal with 
the pathogens . Whether the CFTR mutations increase or decrease homology to 
pathogens is also perhaps irrelevant, as the hyper colonisation by pathogens would be 
an expected consequence of any functional mutation (see discussion); an outcome that 
would favour antibody production that could target any CFTR matching epitopes. As 
antibodies are able to enter cells , such targeting could be relevant to domains in both 
the intracellular and extracellular portions of the CFTR protein.
Pathway analysis of the CFTR interactome (Fig 5)
Pathway analysis of protein interaction networks is a powerful tool for 
divining the functions of particular proteins. Those proteins shown to interact with the 
CFTR protein, from pSTIING, are shown in Table 8. 
Pathway analysis of the CFTR interactome (Table 9) also included the 
autoantigens reported in cystic fibrosis, as their function is also likely to be 
compromised by their respective autoantibodies. This pathway analysis clearly 
demonstrates an important role for the CFTR protein in the immune system and in 
pathogen invasion (Table 9:Fig 5 See 
http://www.polygenicpathways.co.uk/cysfib.htm for coloured KEGG pathways). For 























































































6chemokine signalling and in lysosomal function which is also related to antigen 
processing and pathogen destruction ,as well as in chemokine signalling,  while others 
are involved in bacterial invasion and Vibrio infection or pathogen destruction 
(endocytosis, junctions, phagosomes and lysosomes).These pathways are illustrated in 
Fig 5.
Interaction with viruses in the CFTR interactome.
The virusMINT and HSV-1 interactions  showed that a number of the CFTR 
interacting  proteins also interact with viral proteins from the adenovirus and 
papillomavirus as well as the Epstein-Barr,  Herpes simplex, Hepatitis B and C  and 
HIV-1 viruses (Table 8) , all of which also express proteins with homology to the 
CFTR protein (Table 7) . In other words, certain viral proteins with homology to 
CFTR may bind to the same targets as the CFTR protein and, when present, could 
form an integral part of the CFTR interactome. With the exception of a replete HIV-1 
interaction database, viral/human protein networks are not extensively referenced in 
online databases, and more interactions are likely to exist. 
Certain of the CFTR interactome pathways trace out a route that is used by the 
Herpes simplex virus, and probably other related viruses, during its life cycle. This 
involves entry and endocytosis, entry and exit to and from lysosomes , phagosomes 
and nuclei, and interference with protein processing pathways (see 
http://www.polygenicpathways.co.uk/herpeshost.html for a detailed view). These 
pathways suggest that the CFTR protein is involved in both bacterial and viral defence 
(Fig 5).
The pancreas, cardiac myopathy and the vas deferens in cystic fibrosis
Pancreatic insufficiency and diabetes are common features of cystic fibrosis  as are 
cardiac myopathy and related cardiovascular problems (Moss, 1982).  Bilateral loss of 
the vas deferens in men, or of the uterus and vagina in women are also commonly 
associated with cystic fibrosis . The CFTR/autoantigen pathway analysis indicates that 
the CFTR protein is involved in pancreatic and gastric acid secretion pathways, in 
several pathways related to cardiac myopathy, and in the gonadotrophin signalling 
network, which latter controls the development of the sexual organs.  The 
autoantigens implicated in cystic fibrosis are also members of a signalling network 
related to diabetes (Table 8; Fig 5). These pathways relate to all of the coexisting 
conditions described above. The involvement of the CFTR protein in these signalling 
networks indicates that these associated conditions are a direct result of defects in 
CFTR signalling.
 
Immune related genes that modify cystic fibrosis symptomatology or pathogen 
colonisation 
Many genes that modify the progression or severity of the cystic fibrosis are 
related to immune function. These include inflammation related  genes (interleukins 
IL1B, IL8 and IL10, transforming growth factor-beta1, tumour necrosis factor-alpha 























































































7prostaglandin-endoperoxide synthase genes (COX1 and COX2) as well as CD95, Toll 
receptor TLR9,  T cell receptor beta and HLA antigens .Immune activation and 
inflammation also play a key role in the airways in cystic fibrosis (Machen, 2006b)
There are a large number of MHC molecules, each of which has differing affinity for 
distinct epitopes. HLA-DR2, (which recognises HLA-DRB1*15 and HLA-DRB1*16 
alleles) , as well as HLA-DQB1*0201, HLA-DRB1*0301, and DR7/ DQA*0201 and 
HLA-B-18 have all been associated with cystic fibrosis symptomatology or pathogen 
colonisation . 
Discussion
Nearly 2,000 mutations/polymorphisms have been described in cystic fibrosis 
patients. The most common is the DeltaF508 deletion which is expressed in almost 
70% of patients  and the G551D, G542X, and R553X mutations are also relatively 
common . 20 different mutations were covered by this survey. Several mutations, 
particularly truncations, result in non-expression of the CFTR protein or compromised 
delivery to the cell surface (Davidson & Porteous, 1998). The bacterial and viral 
homology is of less direct relevance to these mutants, although defects in the immune 
and microbial related functions of the CFTR protein would also favour pathogen 
colonisation and immune dysfunction.  These and other mutant proteins result in 
malfunction of the chloride channel encoded by the CFTR protein, with the resultant 
pulmonary pathology associated with cystic fibrosis.
In addition to its actions as a chloride channel, CFTR has a number of other 
properties that are highly relevant to immunity and microbiology. For example it 
controls the efflux of glutathione  which exerts viricidal and bactericidal properties, 
including the S.Aureus and P.Aeruginosa targets   . Glutathione levels are reduced in 
cystic fibrosis  and glutathione aerosols have been reported to ameliorate lung 
epithelia oxidative stress in cystic fibrosis patients  . Clinical trials with glutathione or 
its prodrugs are ongoing . CFTR is also important in pathogen defence, providing the 
chloride for the generation of hypochlorous acid by myeloperoxidase in neutrophil 
phagosomes. This bactericidal mechanism is defective in cystic fibrosis , likely 
rendered the more so by the presence of myeloperoxidase autoantibodies in cystic 
fibrosis .
The CFTR protein is also expressed in lymphocytes  and negatively regulates 
the nuclear factor kappa beta (NFKB) and toll receptor (TLR4) mediated innate 
immune response . The delta F508 mutation has also been shown to inhibit the antigen 
presentation pathway (Hampton & Stanton, 2010), and autoantigens and other 
antigens in cystic fibrosis would therefore not be properly processed. CFTR mutations 
also increase immune activation in mice .
In addition to these effects, CFTR is a pattern recognition receptor that recognises 
P.Aeruginosa . The CFTR protein appears to be involved in P.Aeruginosa ingestion 
and destruction, as the delta508 mutation in infected transgenic mice increases the 
pulmonary P.Aeruginosa burden and decreases its clearance.  This mutation-related 
reduced uptake of the pathogen into epithelial cells favours multiplication of 
P.Aeruginosa within the lungs , The CFTR protein is also an entry portal for 
Chlamydia Trachomatis, and Salmonella Typhi, but not the closely related murine  S. 
typhimurium and the delta508 mutation also reduces pathogen entry into epithelial 
cells . C.Trachomatis binding to CFTR also reduces its chloride channel activity .  Not 























































































8most likely to be present in large quantities.   The Kegg pathway analysis of the CFTR 
binding proteins also revealed a key role in immunity and in pathogen entry and/or 
elimination.
Thus the CFTR mutations might be expected to compromise not only the 
chloride channel, but also the ability to kill pathogens via glutathione, or 
hypochlorous acid. Mutations might also be expected to alter the ability to process 
antigens to pathogens, or to self. CFTR mutations also activate the immune system.
Many of the mutations in the CFTR protein lie within regions that are highly 
immunogenic, and such high immunogenicity would be shared by the viral, bacterial 
and fungal homologues of the protein, of which there are several thousand. The 
autoantigens reported in cystic fibrosis, as well as P.Aeruginosa antigens are also 
homologous to the Delta508 mutant protein, again within regions that are highly 
immunogenic. Given the vast number of pathogen proteins that show homology with 
various regions of the CFTR protein, and the fact that such species are more abundant 
in cystic fibrosis patients, cross-reactivity with the CFTR protein would seem 
inevitable, although to date no antibodies to CFTR have been reported or apparently 
assessed. Although many of the CFTR mutations are intracellular, antibodies do enter 
cells , and even if not mounting an intracellular immune response would be expected 
to bind to the immunogenic regions of the CFTR protein, in effect producing protein 
knockdown, equivalent to the effects of the truncated mutants that fail to reach the cell 
surface. It is also clear that the viral homologues of the CFTR protein are capable of 
binding to CFTR binding partners, potentially modifying the function of CFTR by 
interactome interference. 
Infliximab
Infliximab is a tumour necrosis factor -alpha (TNF) monoclonal antibody used to treat 
autoimmune disorders. TNF antagonism prevents the activation of other inflammatory 
cytokines and leukocyte activation  and this approach is a target in many autoimmune 
and inflammatory conditions (Hoffman, 2009). A recent case study has reported 2 
year remission in a cystic fibrosis patient treated with infliximab . Apart from the use 
of immunosuppressants in cystic fibrosis lung transplant patients, and limited studies 
with cyclosporine, the therapeutic potential of  this class of drug  does not appear to 
have been widely studied .  TNF is one of the autoantigens reported in cystic fibrosis , 
and shares sequence similarities with the CFTR protein (Table 2). Although certain 
TNF antibodies would be expected to cross-react with the CFTR protein, such effects 
would depend upon the epitopes targeted by the antibody, and these details are not 
available.
A possible scenario for cystic fibrosis (Fig 6)
Irrespective of any homology to pathogens, CFTR mutations lead to defects in 
chloride channel function, but also to a reduction in glutathione levels and defects in 
hypochlorous acid production, that would compromise viral and bacterial destruction. 
The channel itself is involved in bacterial entry, and impaired CFTR function reduces 
bacterial entry into epithelial cells, resulting in increased colonisation of the 
extracellular milieu. In this space, the likelihood of encountering immunocompetent 
cells is increased, favouring the production of anti-pathogen antibodies. Pathogen 
binding to the CFTR channel also impairs its function. Such mutations may also 























































































9susceptible to activation. Polymorphisms in immune, inflammation and glutathione 
related genes fine tune this network, modifying its function, for better or worse.
Upon infection, the surfeit of pathogens triggers an immune response that 
generates antibodies to the pathogen that also target human proteins that are 
homologous to the antigenic pathogen proteins, generating the autoantigens observed 
in cystic fibrosis. As judged by epitope homology, antibodies to pathogen proteins 
and to autoantigens may also tag the CFTR protein, rendering it incapable of 
assuming its normal functions. The constant presence of the pathogens and of the 
autoantigens sustains this immune response. Viral infections, in particular, would also 
be expected to modify CFTR function via the theft of interactome partners. Thus, 
antibody knockdown would have the same effect on CFTR function as the mutations 
that prevent CFTR expression, or its delivery to the cell surface. In these cases, the 
antibodies are acting as antagonists, rather than as immune activators. In extreme 
cases, an autoimmune response to the CFTR protein might be expected to damage, or 
kill the cells in which the protein resides. The bioinformatics analysis suggests that 
antibodies to the CFTR protein should be detectable in cystic fibrosis. This does not 
appear to have been assessed, judging from the absence of any mention of CFTR 
autoantibodies in the literature. However, the high titre of pathogen antibodies, whose 
antigen targets are homologous to the CFTR protein, suggests that even low affinity T 
cell epitope binding sites would be saturated.
Taken together, although clearly a genetic disorder, these data suggest that 
cystic fibrosis has a crucial autoimmune component, triggered by pathogens with 
homology to the mutant and related proteins.
Antibacterial agents are already used in cystic fibrosis (Wat, 2003). There are 
no phage or bacterial vaccines as yet, and antiviral agents and vaccination strategies 
could also perhaps be useful. Unfortunately, the repertoire of pathogens colonising 
cystic fibrosis patients is so vast that polypharmacy, with its attendant risks, might 
seem the only plausible option. Clearly the potential benefits of glutathione 
supplementation appear to be promising . Other methods of enhancing pathogen 
defence require further research.
It is possible that immunosuppression might be of benefit in cystic fibrosis. 
This is extremely counter-intuitive, given the problems of multiple infections in these 
patients, but a carefully controlled and supervised clinical trial may well be warranted. 
Indeed, the reported benefits of Infliximab (see above) , although only so far reported 
in a cse study suggest that such approaches may be of more general clinical use.
If the problems in cystic fibrosis stem even partly from autoantigens and 
autoantibodies, then their riddance can only be beneficial.  Immunoadsorption/plasma 
exchange has been reported to be of benefit in the autoimmune disorder, myasthenia 
gravis  and this type of therapy may be applicable to cystic fibrosis, using targeted 
antigen and antibody columns to remove the circulating antibodies and antigens. 
Tryptophan or phenylalanine columns have also been reported to be of use in antibody 
adsorption .  
In summary, CFTR mutations are themselves responsible for bacterial 
hypercolonisation, and for reduced bactericidal and viricidal effects, creating a 
situation where antibody generation to a plethora of pathogens in inevitable. These 
antibodies target other antigens that are homologous to the pathogens’ proteins, and 
these include the various autoantigens that have been recorded in cystic fibrosis. The 
pathogen antigens and autoantigens are both homologous to the CFTR protein itself, 
and antibody related CFTR antagonism is a likely consequence of these effects. 

































































































































Table 1: The antigenicity index (B-cell epitope) for single amino acids defined by 










































































 T cell  epitopes of the F508del mutant and their homologies in relation to 
bacterial and viral proteins. Genera or individual species known to colonise the 
airways in cystic fibrosis are highlighted in bold.
Allele Epitope IC50 
nM
Equivalent Pathogen sequence and 
pathogens
HLA A*0250 TIKENIIGV 3.5 • TIKENIIG: Anaerococcus 
prevotii: Chryseobacterium 
gleum;Prevotella copri
• TIKEFIIGV: Bacillus Cereus





HLA A*0250 IKENIIGVS 8.8 • IKENII-VS: Bacteroides ovatus
• IKEVNIIGV: Filifactor alocis
• KENIIGIVS: Brachyspira 
pilosicoli
• KEQNIIGVS: Clostridium 
perfringens
HLA A*0250 IGVSYDEYRI 44.4 • GISYDEYR: Brachyspira 
pilosicoli
• IGVSY-EYR: Prevotella marshii
• IGDSYDEYR: Acinetobacter 
calcoaceticus
• IIGVSIYDE: Coraliomargarita 
akajimensis
• IIGVSYMDE Brevibacillus brevis
• IIGVSCYDE Xanthomonas 
campestris
• IIGVSYTDE: Burkholderia phage
HLA A*6801 61.7
HLA B*1503 KENIIGVSY 45.9 • KENIIPVSY: Shewanella 
frigidimarina
• KENIIGIS :Clostridium botulinum
• KENDIIGVS: Clostridium 
difficile




• NIIGVS: Staphylococcus aureus
• KENIIG: Staphylococcus aureus
HLA A*3201 63.5
HLA A*0250 NIIGVSYDE 62.6 • IIGVSYD: Pantoea sp AND 
Cellulomonas flavigena and 
Klebsiella sp.AND Cronobacter 










































cellulosum AND Enterobacter 
sakazakii AND Buchnera 
aphidicola AND Pelobacter 
propionicus
• NIIGVSY: Clostridium 
acetobutylicum
HLA B*1503 76.6 • GVSYDEY: Sulfurimonas 
autotrophica AND Eubacterium 
cylindroide
• IIGVSYD: Pantoea sp AND 
Cellulomonas flavigena and 
Klebsiella sp.AND Cronobacter 
turicensis and Sorangium 
cellulosum AND Enterobacter 
sakazakii AND Buchnera 








































Table 3 A summary of some of the pathogen species isolated from cystic fibrosis 
patients and their effects on disease. 
Bacteria Colonisation and effects on symptoms
Achromobacter. 
xylosoxidans
Prevalent in CF patients 
Acinetobacter baumanii Isolated from Russian children with CF 
Burkholderia Cepacia Associated with cystic fibrosis 
Chlamydia pneumoniae Associated with exacerbation of symptoms 
Clostridium difficile Increased in CF patients 
Corynebacterium 
pseudodiphtheriticum
Isolated from CF children’s sputum 
Haemophilus 
influenzae
Often recorded in CF sputum 
Helicobacter pylori Increased in patients with pancreatic sufficiency : Certain 
Mutations protect against H.Pylori infection in patients 
with pancreatic insufficiency 
Klebsiella species Increase in CF patients 
Multiple strains of 
Mycobacteria
UK case report (Brown, 2010)
Pneumocystis jirovecii Isolated from French children with CF 
Prevotella species Isolated from the airways of CF patients 
Pseudomonas 
Aeruginosa




Associated with worsened clinical status 





These species are prevalent in the airways of cystic 
fibrosis patients 
Others Over 60 bacterial genera, not typically associated with 
cystic fibrosis  were isolated from the sputum of CF 
patients including species of :- Actinobacillus, 
Aggregatibacter, Chryseomonas, Flavimonas, 
Haemophilus, Pseudomonas, Strenotrophomonas, 
Vibrio, Acidovorax, Azonexus, Comomonas, Delftia, 
Eikenella, Kingella, Neisseria, Brevundimonas, 
Spingobium, Sphingopyxis, Xanthobacter, Abiotrophia, 
Enterococcus, Gemella, Granulicatella, Lactobacillus, 
Lactococcus, Leuconostoc, Staphylococcus, 
Streptococcus, Butyrovibrio, Catonella, Dialister, 
Megasphaera, Moryella, Oribavterium, Peptoniphilus, 
Peptostyreptococcus, Selenomonas, Veillonella, Bulleida, 
Fusobacterium, Leptotrichia, Actinomyces, Arthrobacter, 
Atopobium, Corynebacterium, Micrococcus, 
Propionibacterium, Rhodococcus, Rothia, Scardovia, 
Tessaracoccus, Bacteroides, Porphyromonas, Prevotella, 










































Epstein-Barr Infection can exacerbate respiratory symptoms (Winnie 
& Cowan, 1992)
Herpes simplex HSV-1 Association has been observed but appears to be rare 
Cytomegalovirus 
(Herpesvirus 5)
Infection is a consistent problem in lung transplant CF 
patients 
Hepatitis B Occasionally observed in CF patients 
Hepatitis C Increased in CF patients 
Influenza Infection worsens symptoms (Dharmaraj & Smyth, 2009)
Respiratory syncytial 
virus
Increased in CF children 
Rhinovirus Rhinoviruses (common cold virus) exacerbate CF 

















































Table 4 Clustal alignment of the autoantigens or of the antigens to P.Aeruginosa 
and S.Maltophilia recorded in cystic fibrosis, with the Delta505F mutant. The 
top 6 high scoring immunogenic amino acids (B cell epitope) are marked in red. 
* = identical : = conserved . = semi-conserved: The autoantigen sequences were 
subsequently compared with S.Aureus (S.Aur) , S.Maltophilia (S.Malt)  and 
P.Aeruginosa (P.Aer) proteins, as shown below the Clustal alignments. These 
alignments are shown bythe boxed regions  or by double underlined regions in 
the autoantigen sequences. Original Lineups are at 
http://www.polygenicpathways.co.uk/cftrpathant.htm
Antigen CFTR Delta508F/antigen/pathogen alignment
Adrenergic 
beta receptor 2 
(Fraser & 
Venter, 1982)
CFTR     MPGTIKEN-IIGVS-Y----DEYRYRSVIKA- 25
ADRB2    VTASIETLCVIAVDRYFAITSPFKYQSLLTKN 32 P.Aer 
         :..:*:   :*.*. *    . ::*:*::.  
ADRB2    VTASIETLCVIAVDRYFAITSPFKYQSLLTKN 32 S.Aur 
         :..:*:   :*.*. *    . ::*:*::.  
ADRB2    VTASIETLCVIAVDRYFAITSPFKYQSLLTKN 32 S.Aur 
         :..:*:   :*.*. *    . ::*:*::.  
ADRB2    VTASIETLCVIAVDRYFAITSPFKYQSLLTKN 32 S.Aur 
         :..:*:   :*.*. *    . ::*:*::.  
ADRB2    VTASIETLCVIAVDRYFAITSPFKYQSLLTKN 32 S.Malt 
         :..:*:   :*.*. *    . ::*:*::.  
ADRB2    VTASIETLCVIAVDRYFAITSPFKYQSLLTKN 32 S.Aur 






BPI  NPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKI 42 S.Aur 
      ** .:: .  *:.*           * :      * . :* 
BPI  NPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKI 42 S.Malt 
      ** .:: .  *:.*           * :      * . :* 
BPI  NPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKI 42 S.Aur 
      ** .:: .  *:.*           * :      * . :* 
BPI  NPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKI 42 P.Malt 
      ** .:: .  *:.*           * :      * . :* 
BPI  NPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKI 42 P.Malt 
      ** .:: .  *:.*           * :      * . :* 
BPI  NPGVVVRISQKGLDYASQQGTAALQKE LK  RIKIPDYSDSFKI 42 P.Aer 
      ** .:: .  *:.*           * :      * . :* 
BPI  NPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKI 42 S.Aur 
      ** .:: .  *:.*           * :      * . :* 
Calgranulin B 
(S100A9) 
CFTR     MP---GTIKENIIGVS--YDEY-------------RYRSVIKA 25
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 P.Aer 
         *.   . ::.**  :   :.:*             .::.::: 
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQ G EFKELVRK 43 P.Aer 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQL E RN  IETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 


















































S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Malt 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNI  ET  IINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGE F KELVRK 43 S.Aur 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 P.Aer 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 P.Aer 
         *.   . ::.**  :   :.:*             .::.:::
S100A9   MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRK 43 S.Aur 





CFTR     MP---G-----TIKENIIGV-------SYD------EYRYRSVIKA 25
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Malt 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 P.Aer 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 P.Aer 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 P.Aer 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPT  L AFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 P.Aer 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 
Bix
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGER P TLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.malt 
         :*   *     :: ::::.:       *:*      :::* . :  
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 
         :*   *     :: ::::.:       *:*      :::* . :
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 
         :*   *     :: ::::.:       *:*      :::* . :
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.malt 
         :*   *     :: ::::.:       *:*      :::* . :
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Malt 
         :*   *     :: ::::.:       *:*      :::* . :
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 P.Aer 
         :*   *     :: ::::.:       *:*      :::* . :
GAD2     LPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQ 46 S.Aur 




CFTR     MP-----------G-TIKENIIG----VSYDEYR--YRSVIKA 25
HSPD1    IPAMT IAK  NAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Aur 
         :*           *  * *:*:     *.**     : .::: 
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 P.Aer 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSE  V GYDAMAGDFVNMVEK 43 P.Aer 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Aur 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Aur 






































HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Aur 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMA GD  F VNMVEK 43 S.Malt 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQ  S SSEVGYDAMAGDFVNMVEK 43 S.Malt 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Malt 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIV  E K IMQSSSEVGYDAMAGDFVNMVEK 43 P.Aer 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Aur 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 P.Aer 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 P.Malt 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNA  G V E GSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 P.Aer 
         :*           *  * *:*:     *.**     : .:::
HSPD1    IPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEK 43 P.Aer 
         :*           *  * *:*:     *.**     : .:::
HSPD1    I P AM T IAKNAGVEGS L IVEKIMQSSSEVGYDAMAGDFVNMVEK 43 S.Aer 
         :*           *  * *:*:     *.**     : .:::
Mucin 1 
(tracheal) 
CFTR     MPG--------TIKENIIGVS-----YDEY------RYRSVIKA 25
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTE AA  S RYNLTISD 44 P.Malt 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLT LA  FREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Malt 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHD V E TQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Malt 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGS VVV  QLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Malt 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGS  VV  VQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 P.Aer 
          **        :::*. *.*      :::*      **. .*. 






































          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
MUC1     RPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISD 44 S.Aur 
          **        :::*. *.*      :::*      **. .*. 
Myeloperoxida
se  MPO 
CFTR     MP------GTIKENIIGVSYDEYRY-RSVIKA 25
MPO      LPTYR S YN  D SVDPRIANVFTNAFRYGHTLIQP 32 S.malt 
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Malt 
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRY  G HTLIQP 32 S.Aur 
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Malt 
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Malt
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRY  G HTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Malt
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Malt
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFT NA  FRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 P.Aer
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Aur
         :*      .::. .* .*  : :** :::*:.






































         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32 S.Malt
         :*      .::. .* .*  : :** :::*:.
MPO      LPTYRSYNDSVDPRIANVFTNAFRYGHTLIQP 32  S.Malt
         :*      .::. .* .*  : :** :::*:.
Proteinase 3 CFTR  MP--------GT-----IKENII-GVS-----------YDEYR-----YRSVIKA----- 
25 PRTN3 
VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYV  D WIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVD W IRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQG I DSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFT RVAL  YVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer 
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *::      
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer








































      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.malt
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDG I IQGI DS  FVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer                  
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Malt
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPD F FTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
S.Aur
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
      :*        *      * :.** *:.           : ::      * . *:: 
PRTN3 VPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRV 
P.Aer
















































      **                *  .: *          :*              *:::    : 









      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 









































      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 
*  **    
RF 
KPGQPPRLLIY G A STRA TG  IPARFSGSGSGTEFTLTISRLQSEDFAVYYCQYNNWPPWFGQGTRVEI
KR S.Malt
      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 
*  **    
RF 
KPGQPPRLLIYGASTRA TG  I PARFSGSGSGTEF T L TISRLQ  S EDFAVYYCQYNNWPPWFGQGTRVEI
KR S.Malt
      **                *  .: *          :*              *:::    : 
*  **    
RF 
KPGQPPRLLIY  G ASTRATGIPARFSGSGSGTEFTLTISRLQSEDFAVYYCQYNNWPPWFGQGTRVEI
KR P.Aer
      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 
*  **    
RF 
KPGQPPRLLIYGASTRATG  I P A RFSGSGSGTEFTLTISRLQSEDFAVYYCQYNNWPPWFGQGTRVEI
KR P.Aer
      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 









































      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 
*  **              
RF 
KPGQPP R LLIYGASTRATGIPARFSGSGSGTEFTLTIS RLQ  SEDFAVYYCQYNNWPPWFGQGTRVEI
KR P.Aer
      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 
*  **              
RF 
KPGQPPRLLIYGASTRATGIPARFSGSGSGTEFTLTISRLQSEDFAVYYCQYNNWPPWFGQGTRV E I 
KR P.Aer
      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 
*  **              
RF 
KPGQPPRLLIYGASTRATGIPARFSGSGSGTEFT L T ISRLQ  S EDFAVYYCQYNNWPPWFGQGTRVEI
KR S.Aur
      **                *  .: *          :*              *:::    : 









































      **                *  .: *          :*              *:::    : 




      **                *  .: *          :*              *:::    : 









      **                *  .: *          :*              *:::    : 


























































































Table 5 : Proteins from S.Aureus, P.Aeruginosa or S.Maltophiulia, that contain 
regions homologous to the regions surrounding vartious CFTR mutants. The 
position of the mutant amino acid is shown in red within the sequences used for 
BLAST analysis.
Mutant Pathogen protein homologue
F508Del ENIIFGVSY
Del = ENIIGVSY 
• >gb|ADI98793.1| probable regulatory protein DeoR 
family [Staphylococcus aureus 
subsp. aureus ED133]8
ENII +SY
• GENE ID: 3237744 SACOL0921 | CBS domain-
containing protein
[Staphylococcus aureus subsp. aureus COL] 
+NIIGV
• GENE ID: 6476997 Smal_2508 | hypothetical protein 
Stenotrophomonas maltophilia R551-3]
+IIGV Y
• >ref|ZP_01368311.1| hypothetical protein 
PaerPA_01005469 [Pseudomonas aeruginosa 
PACS2]
EN+IGV
R74W  NALWRCF • >ref|ZP_06881604.1| adenylate cyclase [Pseudomonas 
aeruginosa PAb1]
NALWR




• GENE ID: 3793024 SAB1831c | hypothetical protein 
[Staphylococcus aureus RF122]
NA WRC
 R117H KEEHSIA • >gb|ACD39272.1| hypothetical protein PACL_0484 
[Pseudomonas aeruginosa]
EEH IA
• gb|EFM07570.1| staphylococcal accessory regulator U 
[Staphylococcus aureus subsp. aureus ATCC BAA-39]
K EHSI
• GENE ID: 5759828 pEDINA_p19 | hypothetical protein 
[Staphylococcus aureus]
KEEH
















































 G124C IYLCIGL • 0891 | RND efflux transporter
[Pseudomonas aeruginosa PA7] 
IYLC G
• GENE ID: 5356552 PSPA7_0172 | 3-oxoacyl-(acyl 
carrier protein) synthase
[Pseudomonas aeruginosa PA7] 
LCIGL
• >gb|ADI96785.1| hypothetical protein SAOV_0248 
[Staphylococcus aureus subsp. 
aureus ED133]
LCIGL
• GENE ID: 6393293 Smlt3043 | putative ISXac3 like 
transposase
[Stenotrophomonas maltophilia K279a] 
YLCI 
V201M  AHFMWIA • GENE ID: 3913891 SAUSA300_0980 | hypothetical 
protein
[Staphylococcus aureus subsp. aureus 
USA300_FPR3757]
HFMWI
• >ref|ZP_06876458.1| putative acyltransferase 
[Pseudomonas aeruginosa PAb1]
MWIA
• GENE ID: 6477949 Smal_0246 | hypothetical 
protein[Stenotrophomonas maltophilia R551-3]
MWIA
 N287K MIEKLRQ • >gb|ADI98383.1| hypothetical protein SAOV_1921c 
[Staphylococcus aureus subsp. aureus ED133]
MIEKL Q
• GENE ID: 6477998 Smal_0813 | hypothetical protein
[Stenotrophomonas maltophilia R551-3]
MIEKLR
• [Pseudomonas aeruginosa LESB58] 
M+EKLR
 R344W IILWKIF • >dbj|BAA88419.1| hydrophobic transmembrane protein 
[Staphylococcus aureus]
IILW IF
• GENE ID: 5355417 PSPA7_0951 | hypothetical protein 
[Pseudomonas aeruginosa PA7]
IL WKIF
• GENE ID: 6476673 Smal_2260 | hypothetical protein
[Stenotrophomonas maltophilia R551-3]
WKIF
 R352E AVTEQFP • emb|CAW29475.1| Gene info linked to CAW29475.1 









































• >gb|ADL22468.1| Ser-Asp rich fibrinogen/bone 
sialoprotein-binding protein SdrD 
[Staphylococcus aureus subsp. aureus JKD6159]
VTEQF
Sbjct 490 VTEQF 494
• GENE ID: 6476745 Smal_3466 | RND efflux system, 
outer membrane lipoprotein,








• GENE ID: 6395375 Smlt1512 | putative exported 
fimbriae-related chaperone
[Stenotrophomonas maltophilia K279a] 
AGATSL
• gb|EFM07900.1| molybdate ABC superfamily ATP 
binding cassette transporter, binding 





• >gb|ADL66280.1| Sec f amily Type I general secretory 
pathway preprotein translocase SecY_1 [Staphylococcus 
aureus subsp. aureus str. JKD6008]
SLLIVI
• GENE ID: 6478455 Smal_1028 | hypothetical protein
[Stenotrophomonas maltophilia R551-3]
LLIV+M
 G480C PSECKIK • gb|EES98134.1| conserved hypothetical protein 
[Staphylococcus aureus subsp. 
aureus TCH130]
SECKI
• GENE ID: 6394958 sucD | succinyl-CoA synthetase 
subunit alpha
[Stenotrophomonas maltophilia K279a] 
P ECKI
• >gb|AAD21623.1| succinyl-CoA synthetase alpha 
subunit [Pseudomonas aeruginosa PAO1]
P ECKI
Sbjct 130 PGECKI 135
 V510D IFGDSYD
  
• GENE ID: 6477620 Smal_0071 | beta-lactamase







































• >gb|ADI96775.1| conserved hypothetical protein 
[Staphylococcus aureus subsp. 
aureus ED133]
IF GDSYD
• >ref|ZP_06881234.1| hypothetical protein 




• >gb|ADL23188.1| oligopeptide ABC superfamily ATP 
binding cassette transporter, 
membrane protein [Staphylococcus aureus subsp. aureus 
JKD6159]
SGDQRA
• >ref|ZP_06881833.1| DNA polymerase I [Pseudomonas 
aeruginosa PAb1]
SGDQR
• gb|ACF51726.1| Gene info linked to ACF51726.1 efflux 
transporter, RND family, MFP subunit 
[Stenotrophomonas maltophilia R551-3]
GDQRA
Sbjct 46 GDQRA 50
 A561E LAR EVYK • A37 thiotransferase enzyme MiaB [Staphylococcus 
aureus ST398]
LARE YK
• GENE ID: 6474448 | AAA ATPase [Stenotrophomonas 
maltophilia R551-3]
AREVY
• GENE ID: 5354737 | hypothetical protein 
[Pseudomonas aeruginosa PA7]
LARE YK




• GENE ID: 6391398 Smlt0713 | hypothetical protein
[Stenotrophomonas maltophilia K279a] 
ESIRAV
• >ref|ZP_06879943.1| succinyl-diaminopimelate 
desuccinylase [Pseudomonas aeruginosa PAb1]
SIRAVT
• >gb|ADL23193.1| phosphate ABC superfamily ATP 
binding cassette transporter, membrane protein 
[Staphylococcus aureus subsp. aureus JKD6159]
E IRAV
Sbjct 180 EAIRAV 185
 S895N KGNNTHS • >pdb|3ITP|A Structure related to 3ITP_A Chain A, 






































Delta+phs F34k At Cryogenic Temperature
KGNNTH
• >ref|ZP_04933853.1| hypothetical protein PA2G_01187 
[Pseudomonas aeruginosa 2192]
KGNN H
• GENE ID: 6474583 Smal_3703 | hypothetical protein
[Stenotrophomonas maltophilia R551-3]
KG NTHS
 D993R TIFRFIQ • >gb|ADL24479.1| intercellular adhesion protein IcaC 
[Staphylococcus aureus subsp. aureus JKD6159]
IFRFI
• GENE ID: 6478446 Smal_1019 | alpha-glucosidase
[Stenotrophomonas maltophilia R551-3]
FRFI+
• GENE ID: 7179795 PLES_56671 | hypothetical protein
[Pseudomonas aeruginosa LESB58] 
+RFIQ
 K1250A GSGASTL • GENE ID: 6477662 Smal_0113 | filamentous 
haemagglutinin family outer membrane









• GENE ID: 6391536 O | presumed capsid scaffolding 
protein (gpo)
[Stenotrophomonas maltophilia K279a] 
FRKKLD
• >gb|ACD38843.1| proline racemase family protein 
[Pseudomonas aeruginosa]
FRK LD 
 G1349D LSHDHKQ • >ref|ZP_06879005.1| hypothetical protein 
PaerPAb_15331 [Pseudomonas aeruginosa PAb1]
LSHD KQ
• GENE ID: 6395416 Smlt1637 | putative transmembrane 
protein











































Table 6 : Tag clouds of the bacterial, viral and fungal species with homology to the 
CFTR polymutant or to the Delta508F CFTR mutant (an octapeptide surrounding the 
deletion point): Tag sizes range from 4 to 30 and are correlated with the number of 
CFTR homologies per pathogen species. The pathogens in red (genera or species) 
have been recorded as overpopulating cystic fibrosis patients (from Table 3). See 
http://www.polygenicpathways.co.uk/cysfib.htm for raw BLAST data.
Polymutant 
vs Bacteria
anthomonas campestris Staphylococcus epidermidis 
Thermoanaerobacter italicus Clostridium sporogenes Pseudomonas Aeruginosa 
Streptococcus mutans Caldicellulosiruptor 
saccharolyticus  Brucella   Roseburia inulinivorans Geobacillus 
thermodenitrificans Gardnerella vaginalis Clostridium 
bartlettii Staphylococcus Aureus Corynebacterium pseudotuberculosis Clostridium butyricum 
Mycobacterium smegmatis Carydibrachium pacificum Staphylococcus carnosus 
BdelloVibrio bacteriovorus Clostridium botulinum 
Clostridium kluyveri Xanthomonas oryzae Lysinibacillus 
sphaericus Caldicelulosiruptor becscii Geobacillus kaustophilus Thermotoga 
lettingae Lactobacillus johnsonii Coprococcus comes 
Orientia tsutsugamushi Pneumocystis jirovecii Clostridium caridivorans 
Thermoanaerobacter mathranii Burkholderia Cepacia Chlamydophila 
pneumoniae Blautia hansenii  Ruminococcus torques   
Streptococcus pneumoniae Stenotrophomonas maltophilia Orientia 
tsutsugamushi Clostridium hiranonis Listeria seeligeri Clostridium   
scindens Verrucomicrobiae bacterium Turicibacter sp ButyriVibrio proteoclasticus 
Thermocrinis albus Haemophilus influenzae Lactobacillus jensenii Porphyromonas gingivalis 
Corynebacterium efficiens Bulleidia extructa Subdoligranulum variabile 
Clostridium spiroforme Shigella Streptococcus sanguinis 
Streptococcus agalactiae Paenibacillus Bacteroides capillosus Bacteroides pectinophilus 
Haemophilus parainfluenzae Alkaliphilus metalliredigens Listeria monocytogenes Escherichia coli Bacillus cereus 
Listeria grayi Streptococcus gallolyticus Symbiobacterium thermophilum 

















































obeum Eubacterium eligens Bacillus pumilus Opitutus terrae marine gamma proteobacterium 
Exiguobacterium sibiricum Erwinia amylovora Bifidobacterium catenulatum 
Xylanimonas cellulosilytica Nostoc sp Microcystis aeruginosa Bacillus cellulosilyticus 
Prevotella Streptococcus suis Bacillus pseudofirmus Cytophaga 
hutchinsonii Gemella haemolysans Geobacillus sp Enterobacter 
cloacae Clostridium lentocellum  Lactobacillus delbrueckii  Dethiobacter alkaliphilus Streptococcus 
Millerii Lactobacillus sakei Bacillus thuringiensis 
Aeromonas hydrophila Parvimonas micra Listeria 
welshimeri Bacillus anthracis Aeromonas salmonicida 
Lysinibacillus fusiformis Aggregatibacter 
aphrophilus Vibrio Desulfitobacterium hafniense Bacillus mycoides 
Lactobacillus crispatus Streptococcus gordonii Streptococcus 
infantarius Dehalococcoides ethenogenes Scardovia 
inopinata Streptococcus uberis Granulicatella 
elegans Prochlorococcus marinus Bacillus subtilis
Polymutant 
Viruses
Measles Xestia c-nigrum granulovirus Foot-and-mouth disease virus 
Influenza A virus West Nile virus Newcastle disease virus Synechococcus phage 
Neodiprion sertifer NPV Theiler's encephalomyelitis virus 
Lettuce mosaic virus Streptococcus phage Leuconostoc phage 
Aeromonas phage Hyphantria cunea 
nucleopolyhedrovirus Hepatitis B virus Gordonia 
terrae phage Dengue virus Human adenovirus  Cryptophlebia   
leucotreta granulovirus Cucumber Bulgarian latent virus Regina ranavirus 
Enterobacteria phage Natrialba phage Human papillomavirus  Human herpesvirus 1 
Synechococcus phage lumpy skin disease virus Breda virus Acanthocystis turfacea Chlorella virus Norwalk-like virus 
Acidianus rod-shaped virus Turkey coronavirus Clostridium phage Jembrana 
disease virus Human astrovirus  Human  Rhinovirus   Pseudomonas phage Staphylococcus phage 
Mamestra configurata NPV-A Staphylococcus phage Black 
queen cell virus Hepatitis E virus Human immunodeficiency virus 1 Batai virus Human herpesvirus 5  Salmonella phage 






































1 Border disease virus Anticarsia gemmatalis nucleopolyhedrovirus Human parvovirus Chuzan virus Mycobacterium phage Infectious 
bronchitis virus Rotavirus GB virus C Escherichia phage Bacillus phage 
Equine arteritis virus Listeria phage Human 
immunodeficiency virus 2 Invertebrate iridescent virus Human 
herpesvirus 2 Hosta virus X Human Respiratory syncytial virus Human herpesvirus 8 Epstein-Barr Stretch 
Lagoon orbivirus Human Herpesvirus 3 
Acinetobacter phage Human bocavirus  Tyuleniy virus   
Feldmannia species virus Vaccinia virus Rubella Human 
herpesvirus 7 Escherichia phage Siberian sturgeon herpesvirus Maguari virus 
Mycoplasma fermentans Human calicivirus Mokola virus Epizootic 
hemorrhagic disease virus Brochothrix phage Hepatitis C virus Lactobacillus 
phage Human T-lymphotropic virus Human enterovirus Choristoneura 
fumiferana Human endogenous retrovirus K Sinorhizobium phage  Japanese   
encephalitis virus Amsacta moorei entomopoxvirus 




Candida albicans Candida glabrata Zygosaccharomyces rouxii Debaryomyces hansenii Laccaria bicolor 
Ustilago maydis Vanderwaltozyma polyspora Ashbya gossypii 
Moniliophthora perniciosa  Penicillium marneffei  Lachancea thermotolerans 
Kluyveromyces lactis Sordaria macrospora 
Aspergillus fumigatus Coprinopsis cinerea  Emericella   
nidulans Podospora anserina Scheffersomyces stipitis Nectria haematococca 
Schizosaccharomyces pombe] Tuber melanosporum Malassezia globosa Aspergillus flavus 
Saccharomyces cerevisiae Cryptococcus neoformans 
Phaeosphaeria nodorum Schizosaccharomyces pombe Aspergillus terreus Aspergillus 
clavatus Ajellomyces capsulatus Aspergillus 
niger Pichia pastoris Lodderomyces elongisporus Schizophyllum commune  Yarrowia lipolytica   Gibberella 
moniliformis Trichophyton verrucosum Aureobasidium pullulans 
Penicillium chrysogenum Phanerochaete chrysosporium Glomus intraradices Alternaria 






































stipitatus Phaeosphaeria nodorum Neurospora crassa Debaryomyces hansenii Nectria 
haematococca Gibberella zeae Ajellomyces dermatitidis Chaetomium globosum  Postia placenta   
Verticillium albo-atrum Kluyveromyces lactis Candida 
dubliniensis Aspergillus nidulans Sclerotinia 
sclerotiorum  Arthroderma benhamiae  Schizosaccharomyces 
japonicus Magnaporthe oryzae Coccidioides posadasii Candida tropicalis 
Uncinocarpus reesii Candida tropicalis Neosartorya fischeri Pichia 
guilliermondii Fusarium oxysporum Coccidioides immitis Meyerozyma 
guilliermondii Botryotinia fuckeliana Pyrenophora tritici-repentis 
Chaetomium globosum Pichia guilliermondii Magnaporthe 
oryzae Clavispora lusitaniae Paracoccidioides 




Stenotrophomonas maltophilia Gordonia bronchialis Catenibacterium 
mitsuokai Lactobacillus ultunensis 
Aggregatibacter actinomycetemcomitans Porphyromonas gingivalis Burkholderia graminis 
Flavobacteriales bacterium Cellulomonas sp Eubacterium 
biforme Neisseria gonorrhoeae Orientia 
tsutsugamushi Pseudomonas syringae Clostridium nexile 
Waddlia chondrophila Fusobacterium varium 
Streptomyces scabiei  Bacillus thuringiensis   Vibrio harveyi Anaerococcus 
vaginalis Actinomyces odontolyticus Pedobacter Selenomonas Bacteroides vulgatus 
Streptococcus Millerii Bacillus cereus Sebaldella 
termitidis Idiomarina loihiensis DesulfoVibrio Clostridium 
spiroforme Treponema denticola Francisella tularensis 
Catenulispora acidiphila Rhizobium leguminosarum Bacteroides 
thetaiotaomicron Clostridium cellulolyticum Clostridium perfringens Frankia 
Photobacterium damselae Bacteroides 






































duerdenii Lactobacillus casei Pediococcus acidilactici Oribacterium Enterococcus faecalis 
Burkholderia cenocepacia Burkholderia glumae Bacteroides 
Hahella chejuensis Francisella philomiragia Rickettsia 
Streptococcus pneumoniae Ethanoligenens harbinense 
Staphylococcus Aureus Azotobacter vinelandii 
Salmonella enterica Novosphingobium aromaticivorans Burkholderia Cepacia 
Clostridium ramosum Lactococcus lactis ButyriVibrio fibrisolvens 
Pseudomonas Aeruginosa Ruminococcus flavefaciens Clostridium 
phytofermentans Streptococcus pyogenes Veillonella Proteus mirabilis Croceibacter atlanticus  Paenibacillus   
Haemophilus influenzae Citrobacter rodentium Candidatus 
Carsonella Symbiobacterium thermophilum 
Xanthomonas Clostridium difficile Actinobacillus pleuropneumonia Alistipes 
putredinis Pneumocystis jirovecii Shewanella violacea Mycobacterium 
tuberculosis Corynebacterium pseudodiphtheriticum Macrococcus 
caseolyticus Pelobacter propionicus Trichodesmium erythraeum Lactobacillus 
salivarius Streptococcus infantarius Psychroflexus torquis  Campylobacter jejuni   Chlamydophila 
pneumoniae Campylobacterales bacterium Candidatus Pelagibacter Photorhabdus 
luminescens Mycobacterium gilvum Clostridium botulinum Mitsuokella multacida 
Saccharophagus degradans Legionella pneumophila 
ParaBacteroides distasonis Sphingomonas 
Anabaena variabilis Corynebacterium 
diphtheriae Chlamydia pneumoniae 
Desulfohalobium retbaense ButyriVibrio crossotus Pseudomonas 
putida Eubacterium dolichum Streptococcus mitis Legionella drancourtii 
Opitutaceae bacterium Prevotella melaninogenica 
Catenulispora acidiphila Leptotrichia goodfellowii 
DeltaF508 
Viruses
Trichoplusia ni Equine infectious anemia virus Hepatitis C virus Escherichia phage Human 
immunodeficiency virus Mycobacterium phage 
Tamiami virus Mushroom bacilliform virus 






































contagiosum virus Cyanophage Lumpy skin disease virus Feline coronavirus 
Dengue virus Human herpesvirus 3 Norovirus Lactobacillus phage Human 
herpesvirus 7 Influenza A virus Human papillomavirus Grapevine virus Antheraea mylitta 
cypovirus Enterobacteria phage Marseillevirus Human 
Herpesvirus 1  Mycobacterium phage Main Drain virus Measles 
Acanthamoeba polyphaga mimivirus Chronic bee 
paralysis virus Japanese encephalitis virus Capsicum chlorosis 
virus Infectious hypodermal and hematopoietic necrosis virus oatpox virus Pellor Fowlpox virus Broad bean true mosaic virus 
Enterobacteria phage Synechococcus phage 
haemorrhagic kidney syndrome virus Northway virus Amsacta 
moorei entomopoxvirus Flavobacterium phage Hepatitis B virus Adoxophyes orana nucleopolyhedrovirus 
Highlands J virus Western equine encephalomyelitis virus Bacillus phage Campylobacter 
phage Human poliovirus Polyomavirus Sclerophthora macrospora virus 
Pseudomonas phage Musca domestica salivary gland hypertrophy virus Deerpox virus Liao ning virus 
Murine cytomegalovirus Toscana virus Soybean chlorotic mottle virus Acinetobacter phage 
Human herpesvirus 6 Epstein-Barr Turdivirus Gloxinia tospovirus Muromegalovirus 
Campylobacter phage Human enterovirus 71 SARS coronavirus Neodiprion sertifer NPV Emiliania 
huxleyi virus Adoxophyes honmai NPV Klebsiella phage Canna 
streak virus Infectious bronchitis virus Acanthocystis turfacea Chlorella virus  Human coxsackievirus   Human 
bocavirus  Epizootic hemorrhagic disease virus   Acidianus filamentous virus 
Foot-and-mouth disease virus Gremmeniella abietina Cotesia plutellae polydnavirus 
Leptospira biflexa temperate bacteriophage Paramecium bursaria 
Chlorella virus  Simian-Human immunodeficiency virus   Erwinia phage Mumps African swine 
fever virus Bidens mottle virus Peanut mottle virus 
Aeromonas phage Human herpesvirus 8 Brochothrix phage Streptococcus phage 
Clostridium phage Human endogenous retrovirus K 
Vaccinia virus Human Respiratory syncytial virus Neisseria meningitidis 
phage Human Rhinovirus wheat yellow mosaic virus Elephant 
endotheliotropic herpesvirus 2 Human endogenous retrovirus Massilia virus 
DeltaF508 
Fungi
Ashbya gossypii Lachancea thermotolerans Arthroderma 
otae Puccinia sorghi Hypocrea jecorina Moniliophthora 






































oryzae Aspergillus terreus Cochliobolus heterostrophus Penicillium marneffei Nectria haematococca 
Lentinula edodes Sclerotinia sclerotiorum Puccinia 
graminis Vanderwaltozyma polyspora Schizosaccharomyces pombe Fusarium 
oxysporum Puccinia recondita Paracoccidioides brasiliensis 
Debaryomyces hansenii Zygosaccharomyces rouxii 
Cadophora gregata Schizosaccharomyces japonicus 
Enterocytozoon bieneusi Dekkera bruxellensis 
Emericella nidulans Ajellomyces capsulatus Coccidioides posadasii 
Coccidioides immitis Verticillium albo-atrum Clavispora lusitaniae 
Botryotinia fuckeliana Talaromyces stipitatus Ajellomyces 
dermatitidis Uncinocarpus reesii Chaetomium globosum Debaryomyces hansenii Postia 
placenta  Trichoderma asperellum   Aspergillus niger Brettanomyces custersianus Coprinopsis cinerea 
Sordaria macrospora Gibberella zeae 
Saccharomyces cerevisiae Candida tropicalis Neurospora crassa 
Penicillium chrysogenum Phaeosphaeria nodorum Neosartorya 
fischeri Aspergillus fumigatus Scheffersomyces stipitis Laccaria bicolo uccinia triticina 
Lodderomyces elongisporus Pichia guilliermondii Puccinia horiana Puccinia 
striiformis Aspergillus clavatus Tuber melanosporum Candida albicans Trichophyton verrucosum Pichia stipitis Arthroderma 
benhamiae Podospora anserina Aspergillus nidulans Yarrowia lipolytica 
Ajellomyces dermatitidis Aspergillus flavus 
Chaetomium globosum Arthroderma otae 
Lodderomyces elongisporus Pichia pastoris Arthroderma 
benhamiae Aspergillus nigere Magnaporthe oryzae Candida dubliniensis Kluyveromyces lactis 
Cryptococcus neoformans Penicillium marneffei Schizophyllum commune 
Malassezia globosa Coprinopsis cine Opegrapha varia Pyrenophora tritici-repentis Encephalitozoon 








































Table 7: Bacterial and viral homologues of the ten  highest affinity CFTR T cell 















HLA A*0250 1:263-271 EMIENIQSV 2.3
HLA A*0211 1:869-877 FLAEVAASL 1.9 LAEVAASL
Slackia heliotrinireducens: 









Ruminococcus sp: Pseudomonas 
mendocina
HLA A*0250 1:869-877 FLAEVAASL 2.1
HLA A*0202 1:869-877 FLAEVAASL 2.3
HLA A*0211 1:199-207 FMWIAPLQV 1.6 MWIAPL
Lactobacillus delbrueckii
WIAPLQ 
Comamonas testosterone: Ferrimonas 













Prevotella oris: Clostridium 
carboxidivorans

















































































HLA A*0211 1:209-217 LLMGLIWEL 1.9 LLMSLIWE
Atopobium vaginae
LLMGLIW 















HLA A*0250 1:209-217 LLMGLIWEL 1.9
HLA A*0219 1:209-217 LLMGLIWEL 2.3
HLA A*0202 1:209-217 LLMGLIWEL 2.4




















































HLA A*0250 1:768-776 VLNLMTHSV 2.1 VLNLMTH











HLA A*0250 1:121-129 YLCIGLCLL
G124C
2.2 LCIGLCL
Bacteroides sp: Bacillus cereus: 




HLA A*0211 1:88-96 YLGEVTKAV 1.7 YLGE-VTKAV
Streptococcus oralis Streptococcus 
pneumoniae and other strep species: 
Eubacterium cylindroide: 
Lysinibacillus fusiformis






































Table 8:  The binding partners of the CFTR protein as defined by pSTIING. The viral 













Apoptosis-inducing factor 1, 
mitochondrial precursor
-
AP1B1 AP-1 complex subunit beta-1 HIV-1
APOA2 Apolipoprotein A-II precursor Hepatitis C, HSV-1  (Carter, 
2010c)  
ATAD3A ATPase family AAA domain-containing 
protein 3A
-
ATP2A2 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 2) ATPase)
-
ATP2A3 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 3 3)
-
ATXN2L Ataxin-2-like protein -
BCR Breakpoint cluster region protein -
C6orf48 Protein G8 -
C8orf55 C8orf55 protein
CALU Calumenin precursor -
CANX Calnexin precursor HIV1, HSV-1 
CAPNS1 Calpain small subunit 1 -
CD59 CD59 glycoprotein precursor HIV-1, HSV-1 (Carter, 2010c)
CDH1 Epithelial-cadherin precursor -
CLCA1
Chloride channel, calcium activated, 
family member 1
-
CLINT1 Clathrin interactor 1 -
CLTA Clathrin light chain A -
CLTCL1 Clathrin heavy chain 2 -
COPB1 Coatomer subunit beta HIV-1 
CSE1L Exportin-2 Epstein-Barr, 
CSTB Cystatin-B -
DAB2 Disabled homolog 2 -
DERL1 Derlin-1 -
DNAJA1 DnaJ homolog subfamily A member 1 Moloney murine leukemia virus
DNAJA2 DnaJ homolog subfamily A member 2 -
DNAJB1 DnaJ homolog subfamily B member 1 HSV-1 (Carter, 2010c)
DNAJC5 DnaJ homolog subfamily C member 5 -
EDG4 Lysophosphatidic acid receptor Edg-4 -
EMD Emerin HSV-1 (Carter, 2010c)
EPS8 Epidermal growth factor receptor kinase 
substrate 8
-









































FAM120A UPF0318 protein FAM120A -




GNA11 Guanine nucleotide-binding protein 
subunit alpha-11 subunit alpha)
-
GNAI2 Guanine nucleotide-binding protein G(i), 
alpha-2 subunit
-
GNB2L1 Guanine nucleotide-binding protein 
subunit beta 2-like 1
Epstein-Barr , Human adenovirus 2 
and 5, HIV-1, 
GOPC Golgi-associated PDZ and coiled-coil 
motif-containing protein
Human papillomavirus type 18  
GPIAP1 GPI-anchored membrane protein 1 Vaccinia Virus 
GRN Granulins precursor HIV-1 
HAX1 HS1-associating protein X-1 Epstein-Barr,  HIV-1 
HCLS1 Hematopoietic lineage cell-specific 
protein
-
HSP90AB1 Heat shock protein HSP 90-beta HSV-1 (Carter, 2010c)
HSPA1A Heat shock 70 kDa protein 1 Epstein-Barr  HSV-1 (Carter, 
2010c)
HSPA1L Heat shock 70 kDa protein 1L Simian virus 40 
HSPA2 Heat shock-related 70 kDa protein 2 -
HSPA5 78 kDa glucose-regulated protein 
precursor protein grp78)
Epstein-Barr, HSV-1 (Carter, 
2010c)
HSPA7 Heat shock 70 kDa protein 7 -
HSPA9B Stress-70 protein, mitochondrial precursor -
HSPB1 Heat-shock protein beta-1 Epstein-Barr,  
HSPD1 60 kDa heat shock protein, mitochondrial 
precursor
Epstein-Barr,  HIV-1




Kab KARP-1-binding protein 1 -
KPNB1 Importin beta-1 subunit HIV-1, HSV-1, Simian virus 40, 




LIMA1 LIM domain and actin-binding protein 1 -
LIN7C Lin-7 homolog C -
LMNA Lamin-A/C Adenovirus, HIV-1, HSV-1, 
Papillomavirus,  HSV-1 (Carter, 
2010c)
LMO7 LIM domain only protein 7 -
LRRFIP2
Leucine-rich repeat flightless-interacting 
protein 2
-








































subfamily A member 5
-





PDCD6 Programmed cell death protein 6 HSV-1 (Carter, 2010c)
PDZK1
PDZ domain-containing protein 1 
exchanger regulatory factor 3)
-
PLD2 Phospholipase D2 -
PLEKHA6
Pleckstrin homology domain-containing 
family A member 6
-
PPP2R1A Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha 
isoform
HIV-1, Papillomavirus, Simian 
virus 40 
PRKAR2A cAMP-dependent protein kinase type II-
alpha regulatory subunit
Adenovirus, Hepatitis B, HIV-1 
PRKDC DNA-dependent protein kinase catalytic 
subunit
Adenovirus, HIV-1, HSV-1, 
PSAP Proactivator polypeptide precursor -
PSMD2 26S proteasome non-ATPase regulatory 
subunit 2
Epstein-Barr 
PSME2 Proteasome activator complex subunit 2 -
RCN1 Reticulocalbin-1 precursor Epstein-Barr 





RNF5 E3 ubiquitin-protein ligase RNF5 -
RPS27A Ubiquitin HIV-1 
RYK Tyrosine-protein kinase RYK precursor -
RYR2 Ryanodine receptor 2 -
S100A7 Protein S100-A7 -
S100A9 Protein S100-A9 -
SEC61A1 Protein transport protein Sec61 subunit 
alpha isoform 1
-




SH3BGRL2 SH3 domain-binding glutamic acid-rich-
like protein 2
-




phosphoprotein 50 exchange regulatory 
cofactor NHE-RF) exchanger)
-
SLC9A3R2 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF2
-
SNX4 Sorting nexin-4 -






































SORL1 Sortilin-related receptor precursor -
SPTLC1 Serine palmitoyltransferase 1 -





TACSTD1 Tumor-associated calcium signal 
transducer 1 precursor
-
TCEB1 Transcription elongation factor B 
polypeptide 1
HIV-1
TCEB2 Transcription elongation factor B 
polypeptide 2
HIV-1
TFG Protein TFG -
TIAM1 T-lymphoma invasion and metastasis-
inducing protein 1
-
TJP1 Tight junction protein ZO-1 -
TJP3 Tight junction protein ZO-3 -
TMEM43 Transmembrane protein 43 -
TMOD3 Tropomodulin-3 -
TPM3 Tropomyosin alpha-3 chain Ectromelia virus strain Moscow 
TRIP12 Thyroid receptor-interacting protein 12 -
UBE2J1 Ubiquitin-conjugating enzyme E2 J1 -
UBE3A Ubiquitin-protein ligase E3A Papillomavirus
UNQ1922 Galactosyltransferase -
VCP
Transitional endoplasmic reticulum 
ATPase ATPase p97 subunit)
-




WSB1 WD repeat and SOCS -containing protein 
1
-



















































CANX, DERL1, DNAJA1, 
DNAJB1,DNAJC5, HSP90AB1, 
HSPA1A, HSPA1L, HSPA2, 
HSPA5,BIP, RNF5, SEC61A1, 
SEC61A2, UBE2J1,VCP, WFS1+ 
CALU 
Endoplasmic reticulum 





TCEB1, TCEB2,TRIP12, UBE2J1, 
UBE3A
Protein degradation via 
this pathway is 








CANX, HSPA1A, HSPA1L, HSPA2, 
HSPA5, HSP90AB1, PSME2
+ Autoantigen TNF
The delta F508 
mutation has also been 
shown to inhibit the 
antigen presentation 
pathway (Hampton & 
Stanton, 2010),
Chemokine 
signal  ling   
pathway  (5)
ADCY8, GNAI2, TIAM1 
+ IL1RAPL1, 
+ autoantigen TNF




Endocytosis  (10) CLTA, CLTLC1, DAB2, HSPA1A, 
HSPA1L HSPA2, PLD2, VPS4A
+ , CLINT1, COPB1,
CFTR is a pattern 
recognition receptor 





CFTR, SEC61A1, SEC61A2, TJP1 Inflammation of airway 
epithelial cells due to 
bacterial colonisation is 
a characteristic feature 
of cystic fibrosis 
(Machen, 2006a)
Bacterial invasion 
of epithelial cells 
 (4)







 + autoantigen TNF 
-
Lysosome  (5) AP1B1, CLTA, CLTCL1, PSAP 
+ CSTB
The CFTR protein is 
involved in lysosomal 
acidification in alveolar 
macrophages and these 
cells are less able to kill 
bacteria  in CFTR 
knockout mice 







































chloride for the 
generation of 










LMNA + Autoantigen TNF
Cardiomyopathy is a 











ATP2A2, EMD, LMNA, RYR2
+ TMEM43
 Cardiac muscle 
contraction (3)
ATP2A2, RYR2, TPM3, 
Pathways in 
cancer  (9)
BCR,CDH1, FAT, HSP90AB1, 
TCEB1, TCEB2, TFG, TPM3 + WSB1
Kidney, thyroid, 
endocrine, lymphoma 
and nonmelanoma skin 
cancer risk is increased 
in cystic fibrosis .
Thyroid cancer 
 (3)
 CDH1, TFG, TPM3. 
Spliceosome  (3) HSPA1A, HSPA1L, HSPA2 -
Pancreatic 
secretion (6)
ADCY8, ATP2A2, ATP2A3, CFTR, 
CLCA1, RYR2
Pancreatic function is 
impaired in CF patients 
Type 1 Diabetes GAD2 , HSPD1 and and TNF 
autoantigens
Diabetes is a frequent 




GNAI2, HCLS1, PPP2R1A, TJP1, 
TJP3 
Gap junction function 
is impaired in cystic 
fibrosis pancreatic duct 
cells  
Airway epithelial tight 
junction function is 
compromised in cystic 
fibrosis (Godfrey, 
1997)
Gap junction  (4) ADCY8, GNA11, GNAI2, TJP1, 
Adherens 
junction  (3)
CDH1, LMO7, TJP1 
Apoptosis (6) AIFM1, CAPNS1, LGALS3 
PRKAR2A, PDCD6, TNF
The calcium, calpain 
caspase apoptosis 




























































ADCY8, GNA11, PLD2; CFTR is expressed in 
the hypothalamus, in 
Gnrh containing cells, 






ADCY8, GNAI2, HSP90AB1 Respiratory epithelial 






ADCY8, CFTR, GNAI2 The CFTR chloride 
channel modulates 
gastric acid secretion 
(Schubert, 2010) 
Long-term 































































The position and nature of the CFTR mutations studied (highlighted in red). Del = deletion; X = stop codon 
termination.




NALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHP 140  R>W R>H G>C
AIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVAL 210  V>M
LMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEA 280 
MEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAV 350  N>K R>W
TRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRK 420  R>K/A/E 
TSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISF 490  K>A M>I G>C
CSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLAR 560  F>Del V>D G>D









































































































































Fig 2 The B-cell and T-cell immunogenic profile of the CFTR mutations. The antigenicity is based on a scan 
















































































The effects of CFTR mutations on B-cell and T-cell immunogenicity. The plots are based on scans of the 
entire CFTR protein. All mutants were used to constitute a polymutant protein. The epitope prediction 
servers generate a table of antigenicity values for each amino acid along the entire length of the protein. The 
delta values reflect subtraction of the native from the CFTR values.   



















































































Fig 4: Examples of P.Aeruginosa or S.Aureus vatches within the polymutant CFTR protein. Highly 
immunogenic regions are in larger font (B cell epitope prediction > 0.5: The Bepipred server sets the epitope 
prediction threshold at 0.35) The alignment regions are boxed and the identical amino acids shaded in grey. 
Red amino acids are the point mutations within the CFTR protein.  
P.Aeruginosa



























































































































Results of the Kegg pathway analysis of the CFTR interactome, including the autoantigens observed in 
cystic fibrosis. The spokes radiating from the CFTR protein contact with proteins within the CFTR 
interactome.  Proteins known to bind to viral proteins are highlighted in white.The pathways on the right 
(entry/endocytosis/intercellular spread/protein removal) are those used by Herpes simplex and manyt other 






























































A pathogenic feed forward cycle in cystic fibrosis
1: CFTR mutations result in chloride channel deficiency with associated problems in fluid homoeostasis/ 
They also favour pathogen accumulation in the extracellular mileu. 2 : CFTR mutations also compromise 
glutathione and hypochlorous acid availability, reducing  bactericidal and viricidal effects. 3: 
Hypercolonistaion by diverse pathogtens results in antibody production. 4: Because of pathogen mimicry 
these antibodies also target autoantigens, and possible the CFTR protein itself. Epitope sharing between 
pathogen/autoantigen and the CFTR protein favours the maintenance of antibody production. 5: Reductions 
in CFTR and autoantigen function, compromises CFTR related pathways, which include those related to the 
associated pathologies of cystic fibrosis. Repeated reductions in CFTR function continue the cycle, resulting 
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